eIF4AI Antibodies

Santa Cruz Biotechnology delivers a wide array of eIF4AI monoclonal antibodies for research focused on protein synthesis and regulation mechanisms. eIF4AI monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). eIF4AI, or eukaryotic translation initiation factor 4A isoform I, plays a crucial role in the initiation of translation by unwinding mRNA secondary structures, thereby facilitating ribosome binding. eIF4AI is essential for the regulation of gene expression and is involved in various cellular processes, including cell growth and proliferation. Research has shown that abnormal eIF4AI activity is linked to several diseases, including cancer, highlighting its significance in therapeutic research. Understanding eIF4AI function can provide valuable insights into cellular mechanisms and potential treatment strategies. Investigating eIF4AI's role in translation initiation continues to reveal new aspects of protein synthesis regulation. Santa Cruz Biotechnology monoclonal antibodies for eIF4AI research support scientists worldwide in advancing our understanding of cellular processes and disease mechanisms.